Method and apparatus for the treatment of obesity

• US 20050038415A1
• Filed: 07/12/2004
• Published: 02/17/2005
• Est. Priority Date: 08/06/2003
• Status: Abandoned Application

• Current Assignee: Ethicon Endo-Surgery, Inc. (Johnson & Johnson)
• Original Assignee: Ethicon Endo-Surgery, Inc. (Johnson & Johnson)
• Inventors: Rohr, William L., Warren, Alison, Freeman, Lynetta, Beaupre, Jean Michael, McKenna, Robert H., Sox, Thomas E.
• Application Number:
  US10/890,304
• Publication Number:
  US 20050038415A1
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A23L 33/175 Amino acids
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A61F 5/0003 Apparatus for the treatment of obesity; Anti-eating devices surgical instruments or methods for treatment of obesity, devices specially adapted therefor A61B17/00; hollow or tubular parts of organs A61F2/04
• CPC Class Codes: A61L 2300/40 characterised by a specific therapeutic activity or mode of action
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2210/1042 Alimentary tract A61M2210/0618 takes precedence
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

The present invention includes methods and materials for manipulating the sense of satiety developed from the gastrointestinal transit of a substance in a mammal, whether the substance be a food or drug compound. The method involves administering a therapeutically effective amount, by a direct delivery route, of a pharmaceutically acceptable formulation comprising nutrients and pharmacological agents to the mammal'"'"'s gastrointestinal tract. The present system is designed to maximize satiety feedback from normal intestinal sensors by small amounts of nutrients or nutrient derivatives, in essence, to “fool” body sensors that are not usually in contact with nutrients unless very large amounts are ingested.

Claims

1. A method of modulating satiety in a subject, the method comprising:

implanting in a subject, at an implantation site, an active agent delivery system comprising a pump and a formulation, the formulation comprising an active agent selected from the group consisting of nutrients and pharmacological agents, wherein the formulation comprises a therapeutically effective amount of the active agent sufficient for inducing or promoting a feeling of satiety in the subject, and delivering the formulation from the active agent delivery system to the subject whereby the active agent enters the gastrointestinal system, whereby the active agent is present at the site of action within the gastrointestinal tract in an amount sufficient to modulate satiety.

2. The method of claim 1, wherein the active agent delivery system is implanted at an implantation site selected from the group consisting of a subcutaneous site, a subdermal site, an intramuscular site, and an intra-adipose tissue site.

3. The method of claim 1, wherein the active agent delivery system is implanted at a subcutaneous site.

4. The method of claim 1, wherein the formulation is delivered at a volume rate of from about 0.01 microliters per day to about 30 milliliters per day.

5. The method of claim 1, wherein the active agent in the formulation is delivered at a rate of from about 0.01 micrograms per hour to 30 milligrams per hour.

6. The method of claim 1, wherein the delivering of the formulation is substantially continuous.

7. The method of claim 1, wherein the active agent delivery system is coupled to a proximal end of a catheter for delivery of the formulation to a delivery site at a distance from the implantation site.

8. The method of claim 1, wherein the delivery site is the small intestines.

9. The method of claim 1, wherein the delivery site is the ileum.

10. The method of claim 1, wherein the pump is selected from the group consisting of an electromechanical pump, an electroosmotic pump, a hydrolytic pump, a piezoelectric pump, an elastomeric pump, a vapor pressure pump, a gravity feed pump, and an electrolytic pump.

11. The method of claim 10, wherein the pump is a programmable rate pump.

12. The method of claim 1, wherein the delivering is for a period of from about 4 weeks to 12 months.

13. The method of claim 1, wherein the formulation comprises an amount of the active agent sufficient to provide for treatment of satiety in the subject for a period of more than 30 days.

14. The method of claim 1, wherein the formulation comprises one or more nutrients selected from the group consisting of amino acids, peptides, proteins, lipids, carbohydrates, vitamins and minerals.

15. The method of claim 1, wherein the formulation comprises a protein hydrolysate selected from the group consisting of casein hydrolysate, whey hydrolysate, casein/whey hydrolysate, soy hydrolysate, and mixtures thereof.

16. The method of claim 1, wherein the formulation comprises one or more amino acids selected from the group consisting of L-phenylalanine, L-tryptophan, L-tyrosine, L-cystine, L-taurine, L-methionine, L-arginine, L-carnitine, leucine, isoleucine, valine, and threonine.

17. The method of claim 1, wherein the formulation comprises one or more saccharides selected from the group consisting of glucose, fructose, mannose, galactose, sucrose, maltose, lactose, maltodextrins and glucose polymers.

18. The method of claim 1, wherein the formulation comprises one or more pharmaceutical agents selected from the group consisting of an active lipid;

a serotonin, serotonin agonist, or serotonin re-uptake inhibitor;

peptide YY, a peptide YY functional analog;

calcitonin gene-related peptide, a functional analog;

CGRP, a CGRP functional analog;

an adrenergic agonist;

an opioid agonist;

or a mixture thereof.

19. The method of claim 1, wherein the formulation comprises one or more active lipids selected from the group consisting of a saturated fatty acid and an unsaturated fatty acid.

20. The method of claim 19, wherein the fatty acid has between 4 and 24 carbon atoms.

21. The method of claim 19, wherein the fatty acid is selected from the group consisting of caprolic acid, caprulic acid, capric acid, lauric acid, myristic acid, oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, linolenic acid, trans-hexadecanoic acid;

elaidic acid, columbinic acid, arachidic acid, behenic acid eicosenoic acid, erucic acid, bressidic acid, cetoleic acid, nervonic acid, Mead acid, arachidonic acid, timnodonic acid, clupanodonic acid, docosahexaenoic acid, and mixtures thereof.

22. The method of claim 19, wherein the fatty acid is selected from the group consisting of oleic acid, dodecanoic acid and glycerol monooleate, and mixtures thereof.

23. The method of claim 19, wherein the active lipid is in the form of pharmaceutically acceptable salts of hydrolyzed fats.

24. The method of claim 19, wherein the active lipid is a sodium or potassium salt selected from the group consisting of caprolate, caprulate, caprate, laurate, myristate, oleate, palmitate, stearate, palmitolate, linolate, linolenate, trans-hexadecanoate, elaidate, columbinate, arachidate, behenate, eicosenoate, erucate, bressidate, cetoleate, nervonate, arachidonate, timnodonate, clupanodonate, docosahexaenoate, and mixtures thereof.

25. The method of claim 19, wherein the active lipid is a sodium or potassium salt selected from the group consisting of oleate and dodecanate salt.

26. The method of claim 1, wherein the formulation additionally comprises a pharmaceutically acceptable carrier.

27. The method of claim 1, wherein the active agent delivery system further comprises a pump operatively connected to a housing, wherein the housing defines a reservoir and the reservoir contains a formulation in an amount sufficient to treat satiety in the subject for a period of at least about 3 days, and wherein the active agent delivery system is completely implanted in the subject.

28. The method of claim 27 wherein the active agent delivery system is coupled to a proximal end of a catheter for delivery of the formulation to a distal end of the catheter at location set apart from the active agent delivery system.

29. The method of claim 28, wherein the pump comprises an osmotic pump.

30. The method of claim 29, wherein the active agent delivery system comprises an amount of active agent sufficient for treatment of satiety in the subject for a period of more than 30 days.

31. A device for the modulating satiety in a subject, comprising:

a controlled active agent delivery system adapted for complete implantation at an implantation site in a subject, the device comprising a pump and a formulation comprising an active agent selected from the group consisting of nutrients and pharmacological agents, wherein the implantation site is selected from the group consisting of a subcutaneous site, an intraperitoneal site, a subdermal site, an intramuscular site, and an intra-adipose tissue site, and wherein the formulation comprises therapeutically effective amount of the active agent sufficient for inducing or promoting a feeling of satiety in the subject for a period of at least about 3 days;

wherein the implantable device is adapted for intestinal delivery of the formulation to a site of action in the subject, whereby the active agent is present at the site of action within the gastrointestinal tract in an amount sufficient to modulate satiety.

32. The device of claim 31, wherein the formulation comprises one or more nutrients selected from the group consisting of amino acids, peptides, proteins, lipids, carbohydrates, vitamins and minerals.

33. The device of claim 32, wherein the formulation comprises an amount of the active agent sufficient for treatment of satiety in the subject for a period of at least about 3 days to about 10 days.

34. The device of claim 32, wherein the formulation comprises an amount of the active agent sufficient for treatment of satiety in the subject for a period of at least about 4 weeks.

35. The device of claim 32, wherein the device delivers the formulation at a rate of from about 0.01 micrograms of the active agent per hour to 300 micrograms of the active agent per hour.

36. The device of claim 32, wherein the device is adapted for delivery of the formulation at a volume rate of from about 0.01 microliters per day to 3 milliliters per day.

37. The device of claim 32, wherein the formulation comprises an amount of the active agent sufficient for treatment of satiety in the subject for a period of more than 7 days.

38. The device of claim 32, wherein the formulation comprises an amount of the active agent sufficient for treatment of satiety in the subject for a period of more than 20 days.

39. The device of claim 32, wherein the formulation comprises an amount of the active agent sufficient for treatment of satiety in the subject for a period of more than 30 days.

40. The device of claim 32, wherein the device further comprises a pump operably connected to housing, wherein the housing defines a reservoir and the reservoir comprises a formulation, wherein the active agent is in an amount sufficient for treatment of satiety in the subject for a period of at least about 3 days, and wherein the active agent delivery system is adapted for delivery of the active agent to the ileum of a subject.